Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis

Дата публикации: 21-07-2026 02:07:37

SAN DIEGO—(BUSINESS WIRE) July 21, 2026 — Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin, an investigational, highly...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)	0	16.04	06-08-2026
2	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy	0	8.61	15-07-2026
3	Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease	0	13.04	14-07-2026
4	HAYA Therapeutics Receives FDA Fast Track Designation for HTX-001	0	20.9	28-07-2026
5	Lundbeck Receives FDA Fast Track Designation for Lu AH69593, an Investigational Orexin 2 Receptor Agonist for Narcolepsy	0	13.22	23-07-2026
6	Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)	0	9.64	22-06-2026
7	Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA	0	13.35	22-06-2026
8	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) as a Treatment for Wet AMD	0	10.76	16-06-2026
9	Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome	0	10.77	18-06-2026
10	Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety	0	10.31	25-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.88. Источник: www.drugs.com.